Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of Systemic Lupus Erythematosus (SLE) confirmed by Systemic Lupus International Collaborating Clinics (SLICC) classification criteria~* Moderate to severe SLE disease activity~* Evidence for at least 1 of the following SLE markers:~  * Anti-dsDNA antibodies confirmed by central laboratory or~ * Low complement confirmed by central laboratory or~ * Antinuclear antibody (ANA) titer of \>= 1:80 in combination with at least 1 of the following: Historical positivity for anti-dsDNA or Positivity for extractable nuclear antigen (anti-ENA) confirmed by central laboratory~* The subject is receiving stable SLE standard-of-care medication~Exclusion Criteria:~* Mixed connective tissue disease, scleroderma, and/or overlap syndromes of SLE~* Subjects with severe neuropsychiatric SLE or other neurological symptoms that in the opinion of the Investigator, would prevent the subject from completing protocol required procedures and assessments.~* New or worsening Class III or IV lupus nephritis~* Chronic kidney failure stage 3b~* Evidence of human immunodeficiency virus (HIV) infection, agammaglobulinemias, T-cell deficiencies, or human T-cell lymphotropic virus-1 infection at any time prior to or during the study~* Clinically significant active or latent infection (eg. chronic viral hepatitis B or C)~* Known tuberculosis (TB) infection, at high risk of acquiring TB infection, or latent TB (LTB) infection~* Live/live attenuated vaccines within 6 weeks prior to the first study drug infusion (Visit 2) or who plan to receive these vaccines during the study or 12 weeks after the final dose of study drug~* History of thromboembolic events within 12 months of screening~* Subject has used protocol defined prohibited medications

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo in a specified sequence for a total of 24 weeks
- DZP dose 1 (Type: EXPERIMENTAL): Dapirolizumab pegol (DZP) dose 1 in a specified sequence for a total of 24 weeks
- DZP dose 2 (Type: EXPERIMENTAL): Dapirolizumab pegol (DZP) dose 2 in a specified sequence for a total of 24 weeks
- DZP dose 3 (Type: EXPERIMENTAL): Dapirolizumab pegol (DZP) dose 3 in a specified sequence for a total of 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).